In a Phase 4 trial (NCT01064284), a chaperone molecule for procoagulant factor VIII (FVIII) was used to block endocytosis in human dendritic cells, thereby protecting FVIII from being endocytosed and subsequently presented to FVIII-specific T cells in patients with Hemophilia A. These clinical trials provide valuable insights into the therapeutic potential of endocytosis inhibitors for various conditions and diseases, including coronavirus infections, Centronuclear Myopathy, Hemophilia A, and pneumonia. Here, F8 is linked to hemophilia A.